CoChat

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation

Open access
DeMicco, Michael, Barrow, Laura, Hickey, Bernadette, Shailubhai, Kunwar, Griffin, Patrick · 2017 · Therapeutic Advances in Gastroenterology

Abstract

Background: Plecanatide, with the exception of a single amino acid replacement, is identical to human uroguanylin and is approved in the United States for adults with chronic idiopathic constipation (CIC). This double-blind, placebo-controlled, phase III study evaluated the efficacy and safety of plecanatide versus placebo in CIC. Methods: Adults meeting modified Rome III CIC criteria were randomized to plecanatide 3 mg ( n = 443), 6 mg ( n = 449), or placebo ( n = 445). Patients recorded bowel movement (BM) characteristics [including spontaneous BMs (SBMs) and complete SBMs (CSBMs)] and rated CIC symptoms in daily electronic diaries. The primary endpoint was the percentage of durable overall CSBM responders (weekly responders for ⩾9 of 12 treatment weeks, including ⩾3 of the last 4 weeks). Weekly responders had ⩾3 CSBMs/week and an increase of ⩾1 CSBM from baseline for the same week. Results: A significantly greater percentage of durable overall CSBM responders resulted with each plecanatide dose compared with placebo (3 mg = 20.1%; 6 mg = 20.0%; placebo = 12.8%; p = 0.004 each dose). Over the 12 weeks, plecanatide significantly improved stool consistency and stool frequency. Significant increases in mean weekly SBMs and CSBMs began in week 1 and were maintained through week 12 in plecanatide-treated patients. Adverse events were mostly mild/moderate, with diarrhea being the most common (3 mg = 3.2%; 6 mg = 4.5%; placebo = 1.3%). Conclusions: Plecanatide resulted in a significantly greater percentage of durable overall CSBM responders and improved stool frequency and secondary endpoints. Plecanatide was well tolerated; the most common AE, diarrhea, occurred in a small number of patients. [ClinicalTrials.gov identifier: NCT02122471]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1756283x17734697

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Patient disposition.
Figure 1. Patient disposition.CC BY-NC · PubMed Central
Figure 2. (a) Percentage of patients in the intent-to-treat population who were durable overall complete spontaneous bowel movement responders, which was the primary efficacy endpoint. **p < 0.01 versus placebo. Error bars represent 95% confidence intervals.Durable overall CSBM responders were defined as patients who fulfilled both ⩾3 CSBMs per week and an increase of ⩾1 CSBM from baseline in the same week for ⩾9 of the 12 treatment weeks, including ⩾3 of the last 4 weeks of treatment. (b) Percentage of patients who were weekly complete spontaneous bowel movement responders. ***p < 0.001, **p < 0.01, *p < 0.05, †p = 0.05 (3 mg) versus placebo. Error bars represent standard error. CSBM, complete spontaneous bowel movement.
Figure 2. (a) Percentage of patients in the intent-to-treat population who were durable overall complete spontaneous bowel movement responders, which was the primary efficacy endpoint. **p < 0.01 versus placebo. Error bars represent 95% confidence intervals.Durable overall CSBM responders were defined as patients who fulfilled both ⩾3 CSBMs per week and an increase of ⩾1 CSBM from baseline in the same week for ⩾9 of the 12 treatment weeks, including ⩾3 of the last 4 weeks of treatment. (b) Percentage of patients who were weekly complete spontaneous bowel movement responders. ***p < 0.001, **p < 0.01, *p < 0.05, †p = 0.05 (3 mg) versus placebo. Error bars represent standard error. CSBM, complete spontaneous bowel movement.CC BY-NC · PubMed Central
Figure 3. (a) Change in weekly complete spontaneous bowel movement frequency from baseline. ***p < 0.001, **p < 0.01, *p < 0.05 versus placebo. Error bars indicated standard error. (b) Change in spontaneous bowel movement weekly frequency from baseline. ***p < 0.001, **p < 0.01, *p < 0.05, †p = 0.051 (3 mg) versus placebo. CSBM, complete spontaneous bowel movement; SBM, spontaneous bowel movement. Error bars indicate standard error.
Figure 3. (a) Change in weekly complete spontaneous bowel movement frequency from baseline. ***p < 0.001, **p < 0.01, *p < 0.05 versus placebo. Error bars indicated standard error. (b) Change in spontaneous bowel movement weekly frequency from baseline. ***p < 0.001, **p < 0.01, *p < 0.05, †p = 0.051 (3 mg) versus placebo. CSBM, complete spontaneous bowel movement; SBM, spontaneous bowel movement. Error bars indicate standard error.CC BY-NC · PubMed Central
Figure 4. Change in weekly stool consistency from baseline, which was measured using the Bristol Stool Form Scale (BSFS). ***p < 0.001, *p < 0.05 versus placebo. Error bars indicate standard error.
Figure 4. Change in weekly stool consistency from baseline, which was measured using the Bristol Stool Form Scale (BSFS). ***p < 0.001, *p < 0.05 versus placebo. Error bars indicate standard error.CC BY-NC · PubMed Central
Figure 5. (a) Percentage of patients with a complete spontaneous bowel movement within 24 h after the first dose of study medication. ***p < 0.001 versus placebo. Error bars indicate 95% confidence intervals. (b) Percentage of patients with a spontaneous bowel movement within 24 h after the first dose of study medication. ***p < 0.001, *p < 0.05 versus placebo. Error bars indicate 95% confidence intervals. CSBM, complete spontaneous bowel movement; SBM, spontaneous bowel movement.
Figure 5. (a) Percentage of patients with a complete spontaneous bowel movement within 24 h after the first dose of study medication. ***p < 0.001 versus placebo. Error bars indicate 95% confidence intervals. (b) Percentage of patients with a spontaneous bowel movement within 24 h after the first dose of study medication. ***p < 0.001, *p < 0.05 versus placebo. Error bars indicate 95% confidence intervals. CSBM, complete spontaneous bowel movement; SBM, spontaneous bowel movement.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 4

  1. Liu D, 2009, Anticancer Res, 29, 3777
  2. Shailubhai K, 2010, Poster presented at Digestive Disease Week (DDW)
  3. Mearin F, 2016, Rev Esp Enferm Dig, 108, 332
  4. Kita T, 1994, Am J Physiol, 266, F342

Cited by

See all 83

Metadata

Authors
DeMicco, M., Barrow, L., Hickey, B., Shailubhai, K., & Griffin, P.
Affiliations
  • Anaheim Clinical Trials (US)
  • Synergy Pharmaceuticals (United States) (US)
Corresponding author
Griffin, Patrick
Venue
Therapeutic Advances in Gastroenterology
Published
2017-10-25
Volume
10
Issue
11
Pages
837-851
ISSN
  • 1756-283X (ISSN-L)
  • 1756-2848
OpenAlex
W2766008196
Cited by
74
References
28
Citations by year
2026: 7 · 2025: 4 · 2024: 5 · 2023: 12 · 2022: 9 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 12 · 2017: 1
FWCI
8.33
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Gastroenterology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
  • Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
Keywords
plecanatide, chronic idiopathic constipation, uroguanylin, guanylate cyclase-C agonist, stool frequency, stool consistency, diarrhea, drug safety, dose comparison

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. https://app.cochat.ai/papers/10.1177/1756283x17734697
The paper
DeMicco, M., Barrow, L., Hickey, B., Shailubhai, K., & Griffin, P. (2017). Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x17734697

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.